GLP-1 coverage in Mississippi
Documented Medicaid fee-for-service status and insurance-mandate activity — not a decision for your member ID.
Sources last checked October 29, 2026
Spot an error? Report a correction
Medicaid (obesity / weight-loss)
KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026
This is the KFF January 2026 fee-for-service survey row for Mississippi. Managed-care plans in the same state can differ. GLP-1s prescribed for type 2 diabetes are covered by every state Medicaid program regardless of this row.
Mississippi Medicaid covers Wegovy, Zepbound and Foundayo for obesity, with criteria effective July 1, 2026.
Preferred agents are Saxenda or Wegovy for ages 12 and older, and Foundayo or Zepbound for ages 18 and older. Contrave, Qsymia, phentermine and amphetamine products are not covered.
Source: Mississippi Division of Medicaid: Anti-obesity Select Agents PA Criteria (07/01/2026 to current, V11), 2026-07-01
Adults qualify with a BMI of 30 or higher, or a BMI of 27 to 29 with at least one weight-related comorbidity such as hypertension, hyperlipidemia, diabetes or prediabetes, obstructive sleep apnea, cardiovascular disease or MASLD. Members 12 to 17 qualify by BMI percentile or weight criteria, depending on the drug.
Source: Mississippi Division of Medicaid: Anti-obesity Select Agents PA Criteria (07/01/2026 to current, V11), 2026-07-01
Every request needs a treatment plan with a 12-month weight or BMI goal and confirmed diet and activity counseling. Initial authorization and reauthorization are each 12 months. Reauthorization asks for at least 9 paid claims in the past year and a weight loss of 5% or more from baseline for adults.
Source: Mississippi Division of Medicaid: Anti-obesity Select Agents PA Criteria (07/01/2026 to current, V11), 2026-07-01
Mississippi's provider education says a DUR+ rule automatically approves Foundayo, Wegovy and Zepbound for adults 18 and older with an obesity diagnosis, for up to 12 months. Other requests, such as members under 18 or overweight members with a comorbidity, need a manual prior authorization.
Source: Mississippi Division of Medicaid: Instructions for Prescribing Select Anti-Obesity Agents (V1), 2026-07-01
Limits include a 30-day supply, 30 tablets per 30 days for oral forms, and no concurrent use of more than one GLP-1 or anti-obesity agent. Medicaid is the payer of last resort, so members with Medicare Part D must exhaust Part D first.
Source: Mississippi Division of Medicaid: Instructions for Prescribing Select Anti-Obesity Agents (V1), 2026-07-01
Diabetes
These documents cover the anti-obesity agents. We have not verified Mississippi Medicaid's criteria for diabetes GLP-1s such as Ozempic and Mounjaro. Check the Division of Medicaid for those rules.
Source: Mississippi Division of Medicaid: Anti-obesity Select Agents PA Criteria (07/01/2026 to current, V11), 2026-07-01
State insurance-mandate activity
Pharmacy Times, "States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments", October 27, 2025
SB 2867 — passed the legislature, vetoed
Also: HealthInsurance.org state coverage tracker (general), 2026. A headline about a bill is not the same as coverage on your card.
What to do with this
Medicaid survey rows and mandate bills are not a prior-authorization approval. Call the number on your ID card and ask whether the drug is covered for your diagnosis.
Full 5-step checklist →Related: All state pages · Medicaid by state · State laws · Cash-pay options